China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Researchers report detailed structural and atomic information for glassy and liquid magnesium silicates, which are important ...

Space-grown crystals could lead to targeted cancer drugsResearchers used space-grown protein crystals to determine the ...